Mepolizumab for eosinophilic COPD with frequent exacerbations: single-centre real-world experience in a phenotype-directed approach
Therapeutic Advances in Respiratory Disease
Published online on February 13, 2026
Abstract
Therapeutic Advances in Respiratory Disease, Volume 20, January-December 2026.
Background:Chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype is linked to frequent exacerbations and increased oral corticosteroid (OCS) use. Mepolizumab, an anti–IL-5 monoclonal antibody, has shown efficacy in eosinophilic ...
Background:Chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype is linked to frequent exacerbations and increased oral corticosteroid (OCS) use. Mepolizumab, an anti–IL-5 monoclonal antibody, has shown efficacy in eosinophilic ...